top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Law and Humanities
Quarterly Reviews

ISSN 2827-9735

Judge Gavel
 Scales of Justice
City Crowds
People in Library
open access

Published: 18 December 2023

Access to Medicine in Post-LDC Era: Challenges in Intellectual Property Law Framework of Bangladesh

Shohane Zaman Prova

Bangladesh University of Professionals

asia institute of research, journal of education, education journal, education quarterly reviews, education publication, education call for papers
pdf download

Download Full-Text Pdf



Pages: 141-152

Keywords: Intellectual Property, Trips Agreement, LDC Graduation, Patent, Medicines


After witnessing the effects of a global pandemic, the need for affordable medicines is higher than ever. Many developing countries are suffering to provide accessible medicine for their citizens. Although Bangladesh, as one of the most successful least developed countries (LDC), has gained remarkable success in the pharmaceutical industry, the impending LDC graduation might have some adverse effects. This study intended to analyze the implications Bangladesh might face and how to work around the new situation. Although most medicines that treat common diseases are off-patent, LDC graduation can increase prices of patented drugs like vaccines as it will limit the direct policy support given to the exporters. As LDC graduation will force Bangladesh to comply with the TRIPS agreement by 2026 rather than 2033, an extension is badly needed. Bangladesh will also have to amend its intellectual property laws to fully comply with the agreement, which puts an added burden. Finally, this study shows that although measures like parallel importation and compulsory licensing may help in easy access to medicine, the best thing for Bangladesh will be to apply for an extension to graduate from the LDC category.


Abbas, M. Z. (2021). Parallel Importation as a Policy Option to Reduce Price of Patented Health Technologies. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 17(4).
Abbott, F.M., & Reichman, J.H. (2007). The Doha Round’s Public Health Legacy: Strategies for the Production and Diffusion of Patented Medicines under the Amended TRIPS Provisions. Journal of International Economic Law, 10, 921.
Bhattacharya, D. (2021, March 21). Bangladesh Qualifies for LDC Graduation: What Next?. The Financial Express.
Cohen-Kohler, J.C., Forman, L. & Lipkus, N. (2008). Addressing Legal and Political Barriers to Global Pharmaceutical Access: Options for Remedying the Impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the Imposition of TRIPS-plus Standards. Health Economics, Policy and Law, 3, 229.
Cullet, P. (2003). Patents and Medicines: The Relationship between TRIPS and the Human Right to Health. International Affairs (Royal Institute of International Affairs 1944-), 79(1), 139–160.
European Centre for Disease Prevention and Control. (2019). HIV/AIDS Surveillance in Europe 2019. 2018 Data. WHO Regional Office for Europe.
Gay, D. & Gallagher, K. (2020). The need to extend the WTO TRIPS pharmaceuticals transition period for LDCs in the COVID-19 era: Evidence from Bangladesh. United Nations CDP policy Review.
Gay, D. (2017). What LDC Graduation Will Mean for Bangladesh’s Drugs Industry. United Nations, LDC Portal- International Support Measures for Least Developed Countries.
Gervais, D. (2012). The TRIPS Agreement: Negotiating History. London: Sweet & Maxwell
Gregory, A. (2021, 21 October). Only 14% of Promised Covid Vaccine Doses Reach Poorest Nations. The Guardian.
Islam, M. (2021, 14 September). LDC Graduation: Evaluating the Implications of Implementing the TRIPS Agreement. The Daily Star.
Islam, M. R. & Dr. Zaman, K. (2021, 11 May). TRIPS Patent Waiver for COVID-19 Vaccines: Is It Legally Necessary. The Daily Star.
Islam, Md. D., Kaplan, W. A., Wirtz, V. J., & Gallagher, K. P. (2022). The Social Costs of Success: The Impact of World Trade Organization Rules on Insulin Prices in Bangladesh upon Graduation from Least Developed Country Status. Asian Development Review, 39(01), 239–279.
Magazine, A. & Raghavan, P. (2021, 18 May). Explained: Intellectual property waiver for Covid-19 vaccines. The Indian Express.
Ranjan, P. (2021, April 12). The case for waiving intellectual property protection for covid-19 vaccines. Policy Commons.
Rahman, M. (2023, February 10). Lessons for Bangladesh as a graduating LDC. The Daily Star.
Razzaque, M.A., Akib, H., Rahman, J., Abbasi, P., Kabir, M., Eusuf, A., Uddin, M., Hasan, E., Zaman, A., Islam, R. & Iftekhar, N. (2020). Navigating New Waters: Unleashing Bangladesh's Export Potential for Smooth LDC Graduation. Bangladesh Enterprise Institute
Singh, R & Singh, N. (2021). Importance of Parallel importation of patented medicines due to ongoing Covid-19 crisis. Nyaayshastra Law Review, 2(1).
Surowiecki, J. (2021, October 27). Pfizer’s Tactics Have Left Poor Countries without Vaccines. MSNBC
Sundaram, J.K. (2021, 3 October). Biden Disappoints: Must Do More, Not Less. The Daily Star.
Urias, E. & Ramani, S.V. (2020). Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence. Journal of International Business Policy 3, 367.
UNAIDS. (2022). Mozambique – Overview.
Warn, C. (2021, 30 October). G20’s Bitter Divide on Global Vaccine Inequality Could Condemn World to an “Endless Pandemic”. Amnesty International.
World Trade Organization. WTO. (n.d.).
World Trade Organizations. (2021, 11 March) Members discuss TRIPS waiver, LDC transition period and green tech role for small business. World Trade Organizations.
WTO | intellectual property (TRIPS) - TRIPS and public health. (n.d.).

bottom of page